Supernus Pharmaceuticals - SUPN Stock Forecast, Price & News

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

Analyst Ratings Changes

SUPN has been the topic of a number of recent analyst reports. StockNews.com raised Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Monday, April 18th. TheStreet lowered Supernus Pharmaceuticals from a "b-" rating to a "c+" rating in a research note on Monday, April 18th.

Supernus Pharmaceuticals Stock Up 4.9 %

Shares of SUPN opened at $32.79 on Monday. Supernus Pharmaceuticals has a 12-month low of $23.15 and a 12-month high of $34.50. The firm has a market capitalization of $1.75 billion, a PE ratio of 32.47 and a beta of 1.04. The stock's fifty day simple moving average is $29.53 and its 200-day simple moving average is $29.90.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Rating) last released its quarterly earnings data on Thursday, August 4th. The specialty pharmaceutical company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.29 by ($0.15). The company had revenue of $170.10 million during the quarter, compared to the consensus estimate of $164.23 million. Supernus Pharmaceuticals had a net margin of 9.12% and a return on equity of 6.98%. The company's revenue for the quarter was up 20.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.43 EPS. Analysts anticipate that Supernus Pharmaceuticals will post 1.51 EPS for the current year.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 39,431 shares of the firm's stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $31.15, for a total transaction of $1,228,275.65. Following the sale, the chief executive officer now directly owns 724,978 shares in the company, valued at approximately $22,583,064.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, VP Tami Tillotson Martin sold 5,000 shares of the stock in a transaction that occurred on Thursday, August 4th. The stock was sold at an average price of $32.98, for a total value of $164,900.00. Following the completion of the sale, the vice president now owns 87,220 shares of the company's stock, valued at approximately $2,876,515.60. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Jack A. Khattar sold 39,431 shares of the firm's stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $31.15, for a total transaction of $1,228,275.65. Following the completion of the transaction, the chief executive officer now directly owns 724,978 shares of the company's stock, valued at $22,583,064.70. The disclosure for this sale can be found here. 7.99% of the stock is currently owned by corporate insiders.